Miyamoto Seiya, LaMantia Anthony S, Duncan Gary E, Sullivan Patrick, Gilmore John H, Lieberman Jeffrey A
St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
Mol Interv. 2003 Feb;3(1):27-39. doi: 10.1124/mi.3.1.27.
Despite great progress in basic schizophrenia research, the conclusive identification of specific etiological factors or pathogenic processes in the illness has remained elusive. The convergence of modern neuroscientific studies in molecular genetics, molecular neuropathology, neurophysiology, in vivo brain imaging, and psychopharmacology, however, indicates that we may be coming much closer to understanding the molecular basis of schizophrenia. Schizophrenia may be a neurodevelopmental and progressive disorder with multiple biochemical abnormalities involving the dopaminergic, serotonin, glutamate, and gamma -aminobutyric acidergic systems. In the near future, biological markers for the illness may come from the combination of diverse assessment techniques. An understanding of the pathophysiology of schizophrenia will be essential to the discovery of preventive measures and therapeutic intervention. Rapidly advancing research into schizophrenia includes diverse etiological hypotheses, and offers directions for future research and treatments.
尽管在精神分裂症基础研究方面取得了巨大进展,但该疾病具体病因或致病过程的确切识别仍然难以捉摸。然而,现代神经科学在分子遗传学、分子神经病理学、神经生理学、活体脑成像和精神药理学方面的研究趋同表明,我们可能正在更接近理解精神分裂症的分子基础。精神分裂症可能是一种神经发育性和进行性疾病,存在涉及多巴胺能、5-羟色胺、谷氨酸和γ-氨基丁酸能系统的多种生化异常。在不久的将来,该疾病的生物标志物可能来自多种评估技术的结合。理解精神分裂症的病理生理学对于发现预防措施和治疗干预至关重要。对精神分裂症的快速推进研究包括各种病因假说,并为未来研究和治疗提供了方向。